Thursday, July 9, 2026

pharma · severe uncontrolled asthma · mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD) · GENB

Generate Biomedicines

Generate Biomedicines clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Somerville, USA HQ
325 Employees
Public company Type
GENB · NYSE Ticker
Company details
Status
Public
HQ
Somerville, USA
Employees
325
Programs
8
Drugs
7
Patents
1
Intelligence · Clinical Programs

Generate Biomedicines projects

6 ClinicalTrials.gov programs sponsored by Generate Biomedicines.

Generate Biomedicines has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. GB-0669

    Generate Biomedicines

    SARS CoV-2

    phase 1 small molecule completed

    1 trial
  2. GB-0895 (SC)

    Generate Biomedicines

    Asthma

    phase 1 mab active

    1 trial
  3. GB-0895-101

    Generate Biomedicines

    mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD)

    phase 1 other active

    1 trial
  4. GB-4362

    Generate Biomedicines

    Advanced Urothelial Cancer

    phase 1 small molecule active

    1 trial
  5. GB-5267 - IV only

    Generate Biomedicines

    Platinum-resistant Ovarian Cancer

    phase 1 mab active

    1 trial
  6. GB-7624

    Generate Biomedicines

    Atopic Dermatitis (AD)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Generate Biomedicines have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.